Medical technology company RaySearch Laboratories AB (STO: RAYB) on Wednesday reported loss after tax of SEK1.0m, or loss per diluted share of SEK0.03, for the third quarter of 2917, from July 2017 to September 2017.
This was a decline over profit after tax of SEK28.9m, or SEK0.84 per diluted share, in Q3 2016.
Net sales for the quarter were SEK111.7m, of which revenues from RayStation were SEK99.1m, as compared with net sales of SEK125.7m, of which revenues from RayStation were SEK112.6m, in Q3 2016.
Order intake, excluding service agreements, for the quarter were SEK02.0m, of which RayStation was SEK92.8m, as compared with order intake of SEK101.1m in Q3 2016, of which RayStation was SEK91.2m.
At the end of the quarter, the order backlog for RayStation was SEK39.1m, as compared with SEK55.5m at the end of Q3 2016.
RaySearch Laboratories develops advanced software solutions for improved radiation therapy of cancer. The company develops and markets the RayStation treatment planning system to clinics all over the world and distributes the products through licensing agreements with leading medical technology companies.
(EUR1.00=SEK9.86)
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva